

## Supplementary Online Content

Robbins JM, Herzig M, Morningstar J, et al. Association of dimethylguanidino valeric acid with partial resistance to metabolic health benefits of regular exercise. Published online June 5, 2019. *JAMA Cardiol*. doi:10.1001/jamacardio.2019.1573

**eMethods 1.** Details of clinical phenotyping in the HERITAGE Family Study

**eMethods 2.** Details of metabolomics platform

**eTable 1.** List of clinical phenotypes examined

**eTable 2.** Associations between baseline DMGV levels and metabolic traits, with and without adjustment for fasting insulin.

**eTable 3.** Changes in DMGV levels after 20 weeks of exercise training

**eTable 4.** Associations between changes in DMGV levels and changes in metabolic traits after exercise training

**eTable 5.** Associations between baseline levels of DMGV and fasting insulin and HDL- trait changes after exercise training.

**eTable 6.** Changes in metabolic traits according to baseline DMGV levels

**eFigure 1.** Cross-sectional relationships between baseline DMGV levels and metabolic traits after adjustment for age, sex, BMI, and abdominal visceral fat

**eFigure 2.** Relationship between baseline DMGV levels and metabolic traits in HERITAGE parents and offspring

**eFigure 3.** Correlation between baseline DMGV levels and changes in DGMV levels after exercise training

This supplementary material has been provided by the authors to give readers additional information about their work.

## **eMethods 1. Details of clinical phenotyping from the HERITAGE Family Study**

### **Anthropometrics and Body Composition**

Body weight, height, and waist and hip circumferences were measured according to standardized procedures, and body density was measured using the hydrostatic weighing technique as described.<sup>1</sup> The mean of the highest three (of ten) measurements was used to calculate percent body fat from body density by using the equation of Siri<sup>2</sup> for Caucasian men and of Lohman<sup>3</sup> for Caucasian women. Fat mass was derived by multiplying body weight by percent body fat. Adipose tissue accumulation and distribution (visceral and subcutaneous) were assessed by abdominal computed tomography at the level of the L4-L5 vertebrae, as previously described.<sup>4,5</sup>

### **Plasma Lipid, Lipoprotein, and Apolipoprotein Measurements**

Fasting blood samples were obtained on two separate days both before and after completion of the exercise training program (about 24 and 72 hours after the last exercise session) and then averaged. Cholesterol and triglyceride (TG) levels were determined in plasma and in lipoprotein fractions using enzymatic methods with a Technicon RA-500 analyzer (Bayer Corp Inc).<sup>6</sup> The plasma very low-density lipoprotein fraction (VLDL; density <1.006 g/mL) was isolated by ultracentrifugation, and the high-density lipoprotein (HDL) fraction was obtained after precipitation of low-density lipoprotein (LDL) in the infranatant (density >1.006 g/mL) with heparin and MnCl<sub>2</sub>. Apolipoprotein B (ApoB) and A1 (ApoA1) concentrations were measured in plasma by the rocket immunoelectrophoretic method of Laurell.<sup>7</sup> Cholesterol content of HDL<sub>2</sub> and HDL<sub>3</sub> subfractions was determined after further precipitation of HDL<sub>2</sub> with dextran sulfate.<sup>8</sup> Reproducibility of all lipid-lipoprotein measurements has been found to be excellent.<sup>9</sup>

### **Lipoprotein Subclass and Particle Size Measurements**

Lipoprotein subclass and particle size analysis was performed in archived, fasting plasma samples before and after exercise training by nuclear magnetic resonance (NMR) spectroscopy at LipoScience, Inc (Raleigh, NC) using the LipoProfile-3 algorithm.<sup>10</sup> Concentrations of large, medium, and small, VLDL-P and HDL-P, large and small LDL-P, and intermediate-density lipoprotein particles (IDL-P), as well as weighted-average VLDL-P, LDL-P, and HDL-P sizes were obtained. A full description of these methods has been previously published.<sup>11</sup>

### **Intravenous glucose tolerance test and insulin and glucose homeostasis variables**

An intravenous glucose tolerance test (IVGTT) was performed the morning after an overnight (12 h) fast before and

after the exercise training program according to the protocol proposed by Walton et al.<sup>12</sup> Details of the IVGTT protocol have been published.<sup>13</sup> IVGTT-derived variables were generated from MINMOD analysis (MINMOD Millennium, version 5.18), and included the insulin sensitivity index ( $S_i$ ), glucose effectiveness ( $S_g$ ), and the acute insulin response to glucose ( $AIR_g$ ). The disposition index ( $D_i$ ) is the product of  $S_i$  and  $AIR_g$  and represents a measure of overall glucose homeostasis and the ability of the  $\beta$ -cell to compensate for insulin resistance. Fasting plasma insulin was measured by radioimmunoassay after polyethylene glycol separation and glucose was assayed using a commercial kit (Diagnostic Chemicals). Post-training samples were obtained 24 hours after the last exercise training session.

## **eMethods 2. Metabolomic profiling of DMGV**

Plasma aliquots of patient samples (10 $\mu$ L) were deproteinized, vortexed, and subjected to centrifugation, and the supernatants were transferred to autosampler vials with glass inserts for LC-MS analysis. Prepared samples were directly injected (10 $\mu$ L) onto an Agilent 1260 system coupled to a 4000-QTrap Quadrupole-Linear ion trap mass spectrometer (AB SCIEX) run in a scheduled Multiple Reaction Monitoring (sMRM) mode. Mass spectrometry data were analyzed using Sciex MultiQuant software. Peaks were manually reviewed for quality by two separate analysts in a blinded manner. In addition, samples were normalized to the average of the nearest neighbor bracketing pair of pooled plasma, which was injected every 20 samples to monitor and correct for temporal drift in mass spectrometry performance.

## eReferences

1. Wilmore JH, Stanforth PR, Domenick MA, et al. Reproducibility of anthropometric and body composition measurements: the HERITAGE Family Study. *Int J Obes Relat Metab Disord*. 1997;21(4):297-303.
2. SIRI WE. The gross composition of the body. *Adv Biol Med Phys*. 1956;4:239-280.
3. Lohman TG. Applicability of body composition techniques and constants for children and youths. *Exerc Sport Sci Rev*. 1986;14:325-357.
4. Ferland M, Després JP, Tremblay A, et al. Assessment of adipose tissue distribution by computed axial tomography in obese women: association with body density and anthropometric measurements. *Br J Nutr*. 1989;61(2):139-148.
5. Després JP, Prud'homme D, Pouliot MC, Tremblay A, Bouchard C. Estimation of deep abdominal adipose-tissue accumulation from simple anthropometric measurements in men. *Am J Clin Nutr*. 1991;54(3):471-477.
6. Leon AS, Rice T, Mandel S, et al. Blood lipid response to 20 weeks of supervised exercise in a large biracial population: the HERITAGE Family Study. *Metabolism*. 2000;49(4):513-520.
7. Avogaro P, Cazzolato G, Bittolo Bon G, Quinci GB, Chinello M. HDL-cholesterol, apolipoproteins A1 and B. Age and index body weight. *Atherosclerosis*. 1978;31(1):85-91.
8. Gidez LI, Miller GJ, Burstein M, Slagle S, Eder HA. Separation and quantitation of subclasses of human plasma high density lipoproteins by a simple precipitation procedure. *J Lipid Res*. 1982;23(8):1206-1223.
9. Després JP, Gagnon J, Bergeron J, et al. Plasma post-heparin lipase activities in the HERITAGE Family Study: the reproducibility, gender differences, and associations with lipoprotein levels. HEalth, RIsk factors, exercise Training and GEnetics. *Clin Biochem*. 1999;32(3):157-165.
10. Jeyarajah EJ, Cromwell WC, Otvos JD. Lipoprotein particle analysis by nuclear magnetic resonance spectroscopy. *Clin Lab Med*. 2006;26(4):847-870.
11. Sarzynski MA, Burton J, Rankinen T, et al. The effects of exercise on the lipoprotein subclass profile: A meta-analysis of 10 interventions. *Atherosclerosis*. 2015;243(2):364-372.
12. Walton C, Godsland IF, Proudler AJ, Felton C, Wynn V. Evaluation of four mathematical models of glucose and insulin dynamics with analysis of effects of age and obesity. *Am J Physiol*. 1992;262(5 Pt 1):E755-762.
13. An P, Hong Y, Weisnagel SJ, et al. Genomic scan of glucose and insulin metabolism phenotypes: the HERITAGE Family Study. *Metabolism*. 2003;52(2):246-253.

**eTable 1. List of metabolic traits examined.**

<b>Lipids, Lipoproteins, Apolipoproteins</b>	<b>Glucose and Insulin traits</b>	<b>Anthropometrics and Body Composition</b>
HDL cholesterol	Fasting plasma glucose	Body Mass Index
HDL triglycerides	Fasting plasma insulin	Waist circumference
LDL cholesterol	Fasting C-peptide	Abdominal visceral fat area
LDL triglycerides	Insulin sensitivity	Abdominal total fat area
VLDL cholesterol	Acute insulin response to glucose	Fat mass
VLDL triglycerides		Fat-free mass
Plasma triglycerides	Disposition index	Body fat percentage
Total plasma cholesterol	Glucose effectiveness	Hip Circumference
Apolipoprotein A1		
Apolipoprotein B		
VLDL apolipoprotein B		
LDL apolipoprotein B		
HDL2 cholesterol		
HDL3 cholesterol		
HDL Particles		
Large HDL Particles		
Medium HDL Particles		
Small HDL Particles		
HDL Size		
IDL Particles		
LDL Particles		
Large LDL Particles		
Small LDL Particles		
LDL Size		
VLDL & Chylomicron Triglyceride		
Large VLDL & Chylomicron Particles		
VLDL & Chylomicron Particles		
Medium VLDL Particles		
Small VLDL Particles		
VLDL Size		

**eTable 2. Associations between baseline DMGV levels and metabolic traits, with and without adjustment for fasting insulin.**

Phenotype	DMGV		DMGV adj. insulin	
	beta	p-value	beta	p-value
VLDL triglycerides in mmol / L	0.190	5.6E-4	0.151	2.2E-3
Large VLDL & Chylomicron Particles	0.189	1.2E-4	0.162	1.6E-3
VLDL Size	0.191	2.4E-4	0.156	4.5E-3
VLDL & Chylomicron Triglyceride (total)	0.167	6.9E-4	0.143	5.3E-3
Plasma triglycerides in mmol / L	0.152	0.001	0.111	0.024
HDL cholesterol in mmol / L	-0.148	0.002	-0.098	0.045
HDL3 cholesterol in mmol / L	-0.162	0.002	-0.110	0.049
LDL Size	-0.157	0.002	-0.128	0.018
Small LDL Particles (total)	0.140	0.003	0.112	0.023
VLDL cholesterol in mmol / L	0.144	0.003	0.105	0.037
Insulin sensitivity	-0.125	0.010	-0.042	0.386
Glucose effectiveness	0.141	0.012	0.118	0.046
Fasting plasma glucose, mmol / L	0.117	0.017	0.072	0.1554
Acute insulin response to glucose	0.124	0.022	0.046	0.385
VLDL apolipoprotein B in mmol / L	0.106	0.036	0.088	0.094

Cross sectional associations between baseline DMGV levels and metabolic traits in a linear regression model adjusted for age, sex, BMI, abdominal visceral fat (left column) plus additional adjustment for insulin (right column)

**eTable 3. Changes in plasma DMGV levels after endurance exercise training in the HERITAGE cohort.**

	<b>T-score</b>	<b>P-value</b>	<b>Median Percent Change</b>
<b>All subjects</b>	-3.78	1.8E-4	-9.4% (-31.1-18.9%)
<b>Parents</b>	-2.43	0.016	-5.1% (-31.1-18.5%)
<b>Offspring</b>	-2.90	0.041	-9.8% (-31.2- 21.0%)

Logarithmically transformed DMGV values were used in a paired Student's *t* test.

**eTable 4. Associations between changes in DMGV levels and changes in metabolic traits after 20 weeks of exercise training.**

Clinical trait	Model 1		Model 2		Model 3	
	Beta	P-value	Beta	P-value	Beta	P-value
Large VLDL & Chylomicron Particles	0.28	6.7E-11	0.28	4.9E-11	0.29	2.1E-11
VLDL & Chylomicron Triglyceride (total)	0.28	1.1E-10	0.29	8.2E-11	0.29	3.8E-11
Fasting C-peptide	0.26	3.4E-08	0.26	2.7E-08	0.23	4.0E-07
VLDL cholesterol, mmol/L	0.25	4.2E-08	0.25	5.6E-08	0.25	3.7E-08
Plasma triglycerides, mmol/L	0.24	8.7E-08	0.24	1.8E-07	0.24	1.0E-07
VLDL triglycerides, mmol/L	0.24	1.0E-07	0.24	1.4E-07	0.25	7.1E-08
Medium HDL Particles	0.21	2.2E-06	0.19	1.1E-05	0.19	1.5E-05
Acute insulin response to glucose	0.21	2.4E-06	0.20	3.0E-06	0.20	6.3E-06
VLDL apolipoprotein B, mmol/L	0.19	5.2E-06	0.20	3.7E-06	0.21	5.0E-07
Fasting insulin	0.19	1.0E-05	0.19	8.5E-06	0.17	2.7E-05
HDL Particles (total)	0.20	1.0E-05	0.19	3.0E-05	0.18	5.1E-05
Fasting glucose, mmol/L	0.19	3.0E-05	0.19	2.1E-05	0.19	2.3E-05
Apolipoprotein B, mmol/L	0.18	1.1E-04	0.18	1.0E-04	0.16	4.7E-04
VLDL Size	0.16	1.7E-04	0.17	5.0E-05	0.17	5.9E-05
Small LDL Particles (total)	0.16	2.7E-04	0.16	2.4E-04	0.16	4.8E-04
Plasma total cholesterol, mmol/L	0.16	5.5E-04	0.16	5.2E-04	0.14	1.9E-03
Medium VLDL Particles	0.13	1.9E-03	0.14	8.9E-04	0.14	7.0E-04

Absolute changes in DMGV and each clinical trait. Effect sizes for each clinical trait are reported per standard deviation (SD) increment of baseline DMGV levels in a linear regression model. Model 1 adjusts for the baseline value of each clinical trait. Model 2 further adjusts for age and sex. Model 3 further adjusts for BMI and the change in BMI after exercise training.



**eTable 5. Associations between baseline levels of DMGV and fasting insulin and HDL-trait changes after exercise training.**

	<b>Insulin</b>	<b>DMGV</b>	<b>DMGV adj. insulin</b>
<b>Apolipoprotein A1</b>			
Beta	-0.005	-0.14	-0.14
P-value	0.92	5.1E-3	5.6E-3
<b>Total HDL-P</b>			
Beta	-0.05	-0.11	-0.10
P-value	0.30	0.03	0.08
<b>Small HDL-P</b>			
Beta	0.05	0.13	0.11
P-value	0.28	3.7E-3	0.04
<b>Medium HDL-P</b>			
Beta	-0.12	-0.19	-0.09
P-value	0.01	2.7E-5	0.11

Effect sizes for each clinical trait are reported per standard deviation increment of DMGV or insulin levels based on a generalized linear model adjusted for age, sex, BMI and changes in BMI after exercise training. "DMGV adj. insulin" includes insulin as a covariate.


**eTable 6. Changes in metabolic traits according to baseline DMGV levels.**

Clinical trait	Model 1		Model 2		Model 3	
	Beta	P-value	Beta	P-value	Beta	P-value
Medium HDL Particles	-0.20	5.4E-6	-0.19	3.4E-5	-0.19	2.7E-5
HDL Particles (total)	-0.18	7.2E-5	-0.15	2.3E-3	-0.11	0.03
Small HDL Particles	0.15	6.1E-4	0.14	2.5E-3	0.13	3.7E-3
Apolipoprotein A1, mmol/L	-0.14	1.9E-4	-0.14	2.3E-3	-0.14	5.1E-3
Insulin sensitivity (S <sub>i</sub> )	-0.13	3.0E-3	-0.11	0.01	-0.04	0.36
IDL Particles	0.11	4.7E-3	0.07	0.09	0.05	0.28
HDL2 cholesterol, mmol/L	-0.11	0.03	-0.10	0.04	-0.10	0.05
Abdominal visceral fat area, cm <sup>2</sup>	0.11	0.03	0.11	0.03	0.02	0.70
Body weight, kg	0.11	0.04	0.12	0.02	0.01	0.53
HDL Size	-0.09	0.05	-0.07	0.16	-0.01	0.71
Fat-free mass, kg	0.08	0.14	0.13	0.01	0.06	0.26


Absolute changes in each clinical trait. Effect sizes for each clinical trait are reported per standard deviation (SD) increment of baseline DMGV levels in a linear regression model. Model 1 adjusts for the baseline value of each clinical trait. Model 2 further adjusts for age and sex. Model 3 further adjusts for BMI and the change in BMI after exercise training.


**eFigure 1. Cross-sectional relationships between baseline DMGV levels and metabolic traits after adjustment for age, sex, BMI, and abdominal visceral fat.**

Effect sizes for each clinical trait are reported per standard deviation (SD) increment of baseline DMGV levels in a linear regression model. Black bars with solid diamonds meet Bonferroni statistical significance ( $p < 0.0011$ ); grey bars with open diamonds meet nominal significance ( $p < 0.05$ ).



**eFigure 2. Relationship between baseline DMGV levels and baseline metabolic traits among HERITAGE generations. Figure 2a is adjusted for age and sex. Figure 2b is further adjusted for BMI and abdominal visceral fat.**






**eFigure 2.**

Effect sizes for each clinical trait are reported per standard deviation (SD) increment of baseline DMGV levels in a linear regression model. Black bars with solid diamonds meet Bonferroni statistical significance ( $p < 0.001$ ); grey bars with open diamonds meet nominal significance ( $p < 0.05$ ).

**eFigure 3. Correlation between baseline DMGV levels and changes in DGMV levels after exercise training in the HERITAGE cohort.**



Pearson's correlation analyses. DMGV levels were logarithmically transformed.